Sights set on Caribbean expansion as talks open with potential regional partners

 Durrant Pate/Contributor 

Pharmaceuticals distributor R.A. Williams has repaid all of its short-term borrowings and is weighing new growth opportunities, including regional expansion.

Shareholders were briefed on these plans and others at the company’s annual general meeting (AGM) last Friday, September 25, 2026. The Spanish town-based R.A. Williams operating cash flow swung by $453 million in the financial year ended April 30, 2026, moving from $172.3 million to a $280.6 million inflow.

This swing gives the pharmaceutical distributor firmer footing to fund its next phase of growth, including a push into the wider Caribbean. During his presentation, Financial Controller Don Smith called operating cash flow “the true metric of our business health”, saying collections were a major contributor.

Trade and other receivables fell by $170.1 million, or 30.7%, to $384.6 million, releasing $168.6 million in cash. Closing cash rose 60.4% to $103.7 million. The stronger cash position allowed R.A. Williams to clear its short-term borrowing entirely, taking the balance from $173.2 million to zero. 

Cutting debt obligations

Smith said the facility was a US-dollar revolving loan used mainly to buy supplies, with terms requiring repayment within 12 months. Long-term loans also fell to $12.9 million from $17.3 million.

Net cash used in financing activities totalled $268.5 million. Asked why the company had moved so firmly to reduce debt, Chief Executive Officer, Audley Reid said a leaner balance sheet leaves the business free to act quickly.

“We’re seeking to grow the business in a very aggressive way, and certainly a company riddled with debt will face some amount of constraints to respond to opportunities that may arise. We believe that reducing our debt puts us on a platform to seize opportunities that may arise in the future,” he continued.

Regional push on in earnest

Reid confirmed R.A. Williams is exploring several options for growth, one of which is expansion across the wider Caribbean over the next 12 to 24 months. The company has already opened talks with potential regional partners, with locally made functional wellness products, including the Sir Henry Turmeric Immunity Shot launched this year, among the lines it hopes to take abroad.

The CEO noted that pricing, competitor analysis, and discussions with local manufacturers will determine the timing. Closer to home, R.A. Williams will launch at least two new antidiabetic medications between the end of the second quarter and the start of the third quarter of the current financial year. 

The Ministry of Health and Wellness has already cleared the products. For Reid, “this launch will put affordable, high-quality options within reach for Jamaican patients managing one of Jamaica’s most prevalent conditions,” adding that it will also capture a larger share of the high-volume chronic care market.

2025/3035 financial highlights

The 2025/26 financial year was one of expansion. Revenue rose 23.4% to $1.98 billion, and gross profit grew 6% to $784.8 million, as R.A. Williams added new portfolios and invested in its distribution network and marketing capacity. That investment lifted selling and distribution costs to $293.5 million from $231.6 million, and the company closed the year with net profit of $16.9 million and total equity of $787.1 million.

For the three months ended July 31, 2026, revenue rose 28% to $534.2 million and net profit reached $47.9 million, reversing a $1.9 million loss in the same period a year earlier. Operating profit nearly quadrupled to $59.8 million.

On the product side, Ryvis Pharma, onboarded early in the year, has become one of the company’s fastest-growing lines. In addition, three new Aristopharma eye drops now cover every stage of dry eye disease, and the Absolut Skin dermatology line has taken R.A. Williams into supermarkets and beauty supply stores for the first time.

The distributor now carries more than 150 prescription and over-the-counter treatments.